Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 1/20 | 0.52 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.52 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.45 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.45 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.44 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.44 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | CD74 | P04233 | 1/20 | 0.43 |
| ▸ | MIF | P14174 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2748458 | 0.88 | FGFR1 (0.53) | FGFR1FGFR4YTHDC1LOXL2CNR1 | |
| SCHEMBL2747454 | 0.76 | EGFR (0.58) | — | |
| SCHEMBL31729695 | 0.72 | MRGPRX4 (0.55) | YTHDC1IDO1MRGPRX4LOXL2CYP4F2 | |
| SCHEMBL13085846 | 0.71 | IDO1 (0.64) | FGFR1YTHDC1IDO1MAPK10 | |
| SCHEMBL3510171 | 0.71 | YTHDC1 (0.45) | YTHDC1IDO1LOXL2ABHD6CYP4F2 | |
| SCHEMBL6085688 | 0.71 | HDAC1 (0.54) | YTHDC1IDO1MAPK10LOXL2ABHD6 | |
| SCHEMBL7830882 | 0.70 | LOXL2 (0.62) | IDO1MRGPRX4MAPK10LOXL2ABHD6 | |
| SCHEMBL3936623 | 0.70 | LOXL2 (0.51) | YTHDC1IDO1MRGPRX4MAPK10LOXL2 | |
| SCHEMBL20569138 | 0.70 | IDO1 (0.53) | YTHDC1IDO1MAPK10LOXL2ABHD6 | |
| SCHEMBL16804361 | 0.69 | YTHDC1 (0.48) | YTHDC1LOXL2OPRD1DRD2TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178543-B2 | growth factor receptor tyrosine kinase inhibitor; anticarcinogenic agents; N-{2-[4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]ethyl}-3-hydroxy-3-methylbutanamide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-05-15 | — | — | US | disclosed |
| US-20090203717-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-08-13 | — | — | US | disclosed |
| US-7507740-B2 | Fused heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-03-24 | — | — | US | disclosed |
| US-20090029973-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-01-29 | — | — | US | disclosed |
| US-20090018335-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-01-15 | — | — | US | disclosed |
| US-20070244132-A1 | Fused Heterocyclic Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-10-18 | — | — | US | disclosed |
| EP-1752457-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-02-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203717-A1 | FUSED HETEROCYCLIC COMPOUND | NOX3, ERBB3, CBR3 | FGFR1 15/4885FGFR4 138/4885YTHDC1 3363/4885 |
| US-20070244132-A1 | Fused Heterocyclic Compound | NOX3, ERBB3, CBR3 | FGFR1 15/4885FGFR4 138/4885YTHDC1 3363/4885 |
| US-20090029973-A1 | FUSED HETEROCYCLIC COMPOUND | NOX3, ERBB3, CBR3 | FGFR1 15/4885FGFR4 138/4885YTHDC1 3363/4885 |
| US-20090018335-A1 | FUSED HETEROCYCLIC COMPOUND | NOX3, ERBB3, CBR3 | FGFR1 15/4885FGFR4 138/4885YTHDC1 3363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.